ArticleCancer cell2020
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer.Chemistry & biodiversity · 2026Article
- Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics.British journal of cancer · 2026Article
- Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5'-Methylthioadenosine in MTAP-Deleted Cancer.Cancer research communications · 2026Article
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Nature communications · 2026Article
- Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer.Molecular cancer · 2026Article
- Cholesterol-Lowering Treatment Blocks Epithelial-Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models.Cancer medicine · 2026Article
- [Standardized Construction of Lung Cancer Organoids and Their Application Progress in the Precise Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.Nature communications · 2026Article
- Role of SCAP in regulation of pancreatic homeostasis, pancreatitis, and tumorigenesis.Oncogene · 2026Article
- Febuxostat enhances the anti-tumor efficacy of 2-fluoroadenine and 5'-methylthioadenosine in MTAP-deleted cancer.bioRxiv : the preprint server for biology · 2026Article
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- Pancreatic cancer EMT‑targeted therapy: Molecular mechanisms and clinical translation (Review).International journal of oncology · 2026Review
- NSDHL as a regulator of lipid peroxidation and ER stress-mediated apoptosis in ovarian cancer.Biology direct · 2026Article
- Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment.Molecular cancer · 2026Review
- Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation.Molecular cancer · 2026Review
- Mevalonate pathway in pancreatic ductal adenocarcinoma: Mechanisms driving metabolic and cellular plasticity.Cancer pathogenesis and therapy · 2026Review
- HHEX-PRKAR2B axis-mediated PKA activation drives glucose metabolism-dependent progression of pancreatic ductal adenocarcinoma.iScience · 2026Article
- Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma.Nature communications · 2026Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 4 institutions in 2 countries.
Linara Gabitova-CornellMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA.
Aizhan SurumbayevaMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA.
Suraj PeriBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
Janusz Franco-BarrazaThe Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Diana RestifoMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA.
Nicole WeitzMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA.
Charline OgierMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA.
Aaron R GoldmanProteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA, USA.
Tiffiney R HartmanMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Ralph FrancesconeThe Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Yinfei TanCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Emmanuelle NicolasMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Neelima ShahThe Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Elizabeth A HandorfBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
Kathy Q CaiCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Alana M O'ReillyMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Ido SlomaChampions Oncology, Inc., Hackensack, NJ, USA.
Rachel ChiaverelliChampions Oncology, Inc., Hackensack, NJ, USA.
Richard A MoffittDepartment of Biomedical Informatics, Stony Brook Cancer Center, Stony Brook, NY, USA.
Vladimir KhazakNexusPharma, Inc., Philadelphia, PA, USA.
Carolyn Y FangCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Erica A GolemisMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Edna CukiermanThe Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Igor AstsaturovMolecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA; The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA; Kazan Federal University, Kazan, Russian Federation. Electronic address: igor.astsaturov@fccc.edu.
Fox Chase Cancer Center · USChampions Oncology (United States) · USStony Brook University · USThe Wistar Institute · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8MTRAINING PROGRAM IN CANCER RESEARCHT32CA009035 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 1985 to 2020
$10.5MMechanisms Controlling Epithelial HomeostasisR01HD065800 · NICHD · RESEARCH INST OF FOX CHASE CAN CTR · PI O'REILLY, ALANA M · 2010 to 2020
$3.9MAn integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skinR01CA232256 · NCI · WISTAR INSTITUTE · PI CUKIERMAN, EDNA, RAJ, ARJUN · 2019 to 2023
$3.0M3D-Adhesion Stromagenesis in Cancer PermissivenessR01CA113451 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CUKIERMAN, EDNA · 2006 to 2016
$2.8MAdvancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1MInteraction of protein-targeted therapeutics and ciliary dynamicsR01DK108195 · NIDDK · RESEARCH INST OF FOX CHASE CAN CTR · PI GOLEMIS, ERICA A. · 2016 to 2020
$2.0MSynergistic targeting of cholesterol metabolism and EGFR signaling in cancerR01CA188430 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2014 to 2018
$1.9MPurchase of a Q Exactive HF mass spectrometer system for metabolomicsS10OD023586 · OD · WISTAR INSTITUTE · PI SPEICHER, DAVID W. · 2017 to 2017
$600kMultiphoton microscopy systemS10OD023666 · OD · RESEARCH INST OF FOX CHASE CAN CTR · PI YEN, TIMOTHY · 2018 to 2018
$600kTargeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer StrategyK22CA160725 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2011 to 2013
$592kOncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cellsR21CA231252 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR, CUKIERMAN, EDNA · 2019 to 2020
$437kNCI NIH HHS K22 CA160725NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA113451NCI NIH HHS R01 CA188430NCI NIH HHS R01 CA232256NCI NIH HHS R21 CA164205NCI NIH HHS R21 CA231252NCI NIH HHS R50 CA221838NCI NIH HHS T32 CA009035NICHD NIH HHS R01 HD065800NIDDK NIH HHS R01 DK108195NIH HHS S10 OD023586NIH HHS S10 OD023666
Abstract
Oncogenic transformation alters lipid metabolism to sustain tumor growth. We define a mechanism by which cholesterol metabolism controls the development and differentiation of pancreatic ductal adenocarcinoma (PDAC). Disruption of distal cholesterol biosynthesis by conditional inactivation of the rate-limiting enzyme Nsdhl or treatment with cholesterol-lowering statins switches glandular pancreatic carcinomas to a basal (mesenchymal) phenotype in mouse models driven by Kras
Indexed as
3-Hydroxysteroid DehydrogenasesAnimalsAtorvastatinBiosynthetic PathwaysCarcinoma, Pancreatic DuctalCell DifferentiationCell Line, TumorCholesterol, LDLEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKaplan-Meier EstimateMice, Inbred C57BLMice, Knockout3-Hydroxysteroid DehydrogenasesAtorvastatinCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsNsdhl protein, mouseTransforming Growth Factor betacholesterol metabolismepithelial-to-mesenchymal transitionpancreatic cancerTGF-β signaling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.